This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Astrazeneca (AZN) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
The latest trading day saw Astrazeneca (AZN) settling at $64.42, representing a -1.26% change from its previous close.
Will Rising Costs Hurt HCA Healthcare's (HCA) Q3 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) third-quarter results are likely to reflect an increased occupancy rate and a lower average length of stay.
Can Growing Visits Aid Teladoc's (TDOC) Earnings in Q3?
by Zacks Equity Research
Teladoc's (TDOC) third-quarter results are likely to reflect growth in BetterHelp paying users.
AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Astrazeneca (AZN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Can Centene's (CNC) Q3 Earnings Beat on Membership Growth?
by Zacks Equity Research
Centene's (CNC) third-quarter results are likely to reflect higher premiums and lower cost of services.
AstraZeneca's (AZN) Tagrisso Combo Gets FDA's Priority Review
by Zacks Equity Research
The FDA accepts and grants priority review to AstraZeneca's (AZN) sNDA, seeking approval of Tagrisso combined with chemotherapy as a first-line treatment for EGFR-mutated advanced NSCLC. A decision is due in first-quarter 2024.
UnitedHealth Group (UNH) Q3 Earnings Beat, Boosts '23 EPS View
by Zacks Equity Research
UnitedHealth Group's (UNH) management presently forecasts adjusted net EPS between $24.85 and $25.00 for 2023.
J&J (JNJ) to Report Q3 Earnings, Its First After Unit Spin-Off
by Zacks Equity Research
J&J's (JNJ) third-quarter results are the first quarterly update for the new company after the Consumer Health spin-off.
Why the Market Dipped But (AZN) Gained Today
by Zacks Equity Research
Astrazeneca (AZN) concluded the recent trading session at $68.11, signifying a +0.15% move from its prior day's close.
Can Elevance's (ELV) Q3 Earnings Beat on Carelon Strength?
by Zacks Equity Research
The third-quarter results of Elevance (ELV) are likely to reflect strong rate adjustments and membership growth in the Health Benefits business.
The Zacks Analyst Blog UnitedHealth, Chevron, AstraZeneca, Adobe and Pfizer
by Zacks Equity Research
UnitedHealth, Chevron, AstraZeneca, Adobe and Pfizer are part of the Zacks Analyst Blog.
Top Analyst Reports for UnitedHealth, Chevron & AstraZeneca
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Chevron Corporation (CVX) and AstraZeneca PLC (AZN).
Lexicon's (LXRX) Inpefa Gets Preferred Status at Express Scripts
by Zacks Equity Research
A pharmacy benefit manager decides to place Lexicon's (LXRX) heart failure drug as a preferred product on Medicare national formularies on Nov. 1. The stock jumped 12% post this announcement.
Will UnitedHealth's (UNH) UnitedHealthcare Unit Aid Q3 Earnings?
by Zacks Equity Research
UnitedHealth's (UNH) third-quarter results are expected to benefit from an increase in UnitedHealthcare's Community & State revenues as well as the number of people it served.
Can High Medical Costs Affect UnitedHealth (UNH) Q3 Earnings?
by Zacks Equity Research
UnitedHealth's (UNH) third-quarter results are likely to reflect growth in memberships and premium levels.
Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Astrazeneca (AZN) Gained But Lagged the Market Today
by Zacks Equity Research
Astrazeneca (AZN) concluded the recent trading session at $67.42, signifying a +0.81% move from its prior day's close.
Pharma Stock Roundup: LLY Offers to Buy POINT Biopharma & Other Updates
by Kinjel Shah
Eli Lilly (LLY) offers to buy POINT Biopharma for approximately $1.4 billion. Sanofi (SNY) partners with Teva for co-developing immunology candidate.
Sanofi (SNY) Stock Outperforms Industry YTD: What's Next?
by Zacks Equity Research
Continued strong sales of Dupixent, contributions from new product launches and positive pipeline progress are likely to keep Sanofi's (SNY) stock afloat.
Astrazeneca (AZN) Advances But Underperforms Market: Key Facts
by Zacks Equity Research
Astrazeneca (AZN) concluded the recent trading session at $66.62, signifying a +0.54% move from its prior day's close.
AstraZeneca (AZN) Settles Heartburn Drugs Lawsuits for $425M
by Zacks Equity Research
AstraZeneca (AZN) agrees to pay $425 million to settle lawsuits related to heartburn drugs, Nexium and Prilosec.
J&J's (JNJ) Rybrevant Combo Meets Primary Goal in NSCLC Study
by Zacks Equity Research
J&J (JNJ) meets the primary goal in the late-stage study of the combination therapy of Rybrevant and lazertinib against Tagrisso for EGFR-mutated first-line NSCLC.
AstraZeneca (AZN) Key Drugs to Aid Growth, Pipeline Strong
by Zacks Equity Research
AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Fasenra and Farxiga should keep driving revenues. Its pipeline is strong, with several phase III data readouts lined up.
Is it Time to Buy Pfizer, Moderna, or AstraZeneca's Stock?
by Shaun Pruitt
Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings potential.
Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Astrazeneca (AZN) closed at $67.42, marking a -0.77% move from the previous day.